Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

Phase 1

Terminated

• Conditions: Acute Graft Versus Host Disease

• Registration Number: NCT00032773
• Lead Sponsor: Astex Pharmaceuticals, Inc.

Brief Summary

To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01-30
• Study First Submitted: 2002-04-02
• Study First Submitted QC: 2002-04-03
• Study First Posted: 2002-04-04
• Primary Completion: 2005-11-03
• Study Completion: 2005-11-03
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-01
• Last Update Posted: 2024-08-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States